Please login to the form below

Stem Cell Therapeutics

This page shows the latest Stem Cell Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Bayer takes control of BlueRock stem cell joint venture

Deal values BlueRock at $1bn. Bayer is buying out private equity partner Versant Ventures and founders in its cell therapy joint venture BlueRock Therapeutics for $240m, three years after setting up ... The start-up intends to develop off-the-shelf

Latest news

Bayer helps bankroll new stem cell company BlueRock

Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies. There is a new player on the stem cell therapy stage, thanks to $225m in start-up funding from Bayer ... BlueRock's founding and scientific investigation team
Orphan status for Stem Cell's leukaemia drug

Tigecycline wins FDA rare disease designation. US regulators have granted orphan drug status to tigecycline, a cancer drug in development by Stem Cell Therapeutics. ... Tigecycline is being investigated by Stem Cell Therapeutics for its use in the
UK regenerative medicine projects get £8.5m boost

Novel stem cell manufacturing technologies. • Cell labelling and tracking technologies for quality control and monitoring in the body. • ... Regenerative medicine is an interdisciplinary approach that spans tissue engineering, developmental and stem
Survival strategy

Licenser/Partner. Product/Technology. Development status. Headline ($m). Mesoblast/Cephalon. Stem cell therapeutics in CHF. ... Immunotherapy company acquisition. . 428. Theramex/Teva. Branded product company acquisition. . 368. Evotec/MedImmune.
Diabetes favoured

and Oncomed's $428m strategic alliance with Bayer Schering Pharma (BSP) to discover, develop and commercialise novel anti-cancer stem cell therapeutics. ... Anti-cancer stem cell therapy platform. Discovery. 428. Ascenta Therapeutics/sanofi-aventis.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

Deal Watch table for October 2013

Commercialisation. Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast . ... Asset acquisition. Mesenchymal stem cell business, including Prochymal (approved). 100. †Hutchison MediPharma / Eli Lilly.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Principal Medical Writer: Varies on experience

Senior Content Editor - Biotechnology: Salary TBC

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

PMHub

Add my company

certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....
Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...